284 related articles for article (PubMed ID: 34830594)
21. Efficacy of the HLA-B
Park HW; Kim DK; Kim SH; Kim S; Chae DW; Yang MS; Oh YK; Lee JP; Jung JW; Shin J; Hwang JH; Kang MG; Kim SM; Kwon SK; Kim HY; Kim MH; Kim SJ; Ryu DR; Cho YJ; Jee YK; Kim SM; Lee EK; Kim JY; Cho HS; Jeong YY; Kim SH; Jun JB; Park JS; Kim GH; Kim S; Jung HY; Lee JM
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1271-1276. PubMed ID: 30580048
[TBL] [Abstract][Full Text] [Related]
22. Mechanistic insights into antiretroviral drug-induced liver injury.
Pillaye JN; Marakalala MJ; Khumalo N; Spearman W; Ndlovu H
Pharmacol Res Perspect; 2020 Aug; 8(4):e00598. PubMed ID: 32643320
[TBL] [Abstract][Full Text] [Related]
23. Outcomes and Predictors of Mortality in Patients With Drug-Induced Liver Injury at a Tertiary Hospital in South India: A Single-Centre Experience.
Sunil Kumar N; Remalayam B; Thomas V; Ramachandran TM; Sunil Kumar K
J Clin Exp Hepatol; 2021; 11(2):163-170. PubMed ID: 33746440
[TBL] [Abstract][Full Text] [Related]
24. Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.
Sarges P; Steinberg JM; Lewis JH
Drug Saf; 2016 Sep; 39(9):801-21. PubMed ID: 27142208
[TBL] [Abstract][Full Text] [Related]
25. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
Treem WR; Palmer M; Lonjon-Domanec I; Seekins D; Dimick-Santos L; Avigan MI; Marcinak JF; Dash A; Regev A; Maller E; Patwardhan M; Lewis JH; Rockey DC; Di Bisceglie AM; Freston JW; Andrade RJ; Chalasani N
Drug Saf; 2021 Feb; 44(2):133-165. PubMed ID: 33141341
[TBL] [Abstract][Full Text] [Related]
26. The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients.
Devarbhavi H; Joseph T; Sunil Kumar N; Rathi C; Thomas V; Prasad Singh S; Sawant P; Goel A; Eapen CE; Rai P; Arora A; Leelakrishnan V; Gopalakrishnan G; Vardhan Reddy V; Singh R; Goswami B; Venkataraman J; Balaraju G; Patil M; Patel R; Taneja S; Koshy A; Nagaraja Rao P; Kumar Sarin S; Rathi P; Dhiman R; Duseja AK; Vargese J; Kumar Jain A; Wadhawan M; Ranjan P; Karanth D; Ganesh P; Nijhawan S; Krishna Dhali G; Adarsh CK; Jhaveri A; Nagral A; Rao P; Shalimar
J Clin Exp Hepatol; 2021; 11(3):288-298. PubMed ID: 33994711
[TBL] [Abstract][Full Text] [Related]
27. [Significance of histological assessment in drug-induced liver injury].
Jiang LN; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2023 Apr; 31(4):349-354. PubMed ID: 37248975
[TBL] [Abstract][Full Text] [Related]
28. Idiosyncratic drug-induced liver injury: an update on the 2007 overview.
Hussaini SH; Farrington EA
Expert Opin Drug Saf; 2014 Jan; 13(1):67-81. PubMed ID: 24073714
[TBL] [Abstract][Full Text] [Related]
29. Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators.
Chu MT; Chang WC; Pao SC; Hung SI
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672685
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM.
Kobayashi T; Iwaki M; Nogami A; Yoneda M
J Clin Transl Hepatol; 2023 Oct; 11(5):1239-1245. PubMed ID: 37577239
[TBL] [Abstract][Full Text] [Related]
31. Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study.
Rodríguez A; García-García I; Martínez de Soto L; Gómez López De Las Huertas A; Borobia AM; González-Torbay A; Akatbach-Bousaid I; González-Muñoz M; Ramírez E
Front Pharmacol; 2022; 13():819589. PubMed ID: 35370653
[No Abstract] [Full Text] [Related]
32. Review article: drug-induced liver injury in clinical practice.
Björnsson E
Aliment Pharmacol Ther; 2010 Jul; 32(1):3-13. PubMed ID: 20374223
[TBL] [Abstract][Full Text] [Related]
33. Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury.
Das S; Behera SK; Xavier AS; Velupula S; Dkhar SA; Selvarajan S
Clin Drug Investig; 2018 Mar; 38(3):211-218. PubMed ID: 29185238
[TBL] [Abstract][Full Text] [Related]
34. Newly identified genetic variants associated with idiosyncratic drug-induced liver injury.
Stolz A
Curr Opin Gastroenterol; 2022 May; 38(3):230-238. PubMed ID: 35645018
[TBL] [Abstract][Full Text] [Related]
35. HLA Association with Drug-Induced Adverse Reactions.
Fan WL; Shiao MS; Hui RC; Su SC; Wang CW; Chang YC; Chung WH
J Immunol Res; 2017; 2017():3186328. PubMed ID: 29333460
[TBL] [Abstract][Full Text] [Related]
36. Idiosyncratic drug-induced liver injury: an overview.
Hussaini SH; Farrington EA
Expert Opin Drug Saf; 2007 Nov; 6(6):673-84. PubMed ID: 17967156
[TBL] [Abstract][Full Text] [Related]
37. Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment.
Mullins C; Beaulac K; Sylvia L
Ann Pharmacother; 2020 Jun; 54(6):526-532. PubMed ID: 31786964
[No Abstract] [Full Text] [Related]
38. Idiosyncratic Drug-Induced Liver Injury Associated With and Without Drug Reaction With Eosinophilia and Systemic Symptoms.
Devarbhavi H; Kurien SS; Raj S; Patil M; Gowda V; Kothari K; Singh R
Am J Gastroenterol; 2022 Oct; 117(10):1709-1713. PubMed ID: 35862835
[TBL] [Abstract][Full Text] [Related]
39. Causality assessment for suspected DILI during clinical phases of drug development.
Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
[TBL] [Abstract][Full Text] [Related]
40. [Clinical and pathological features in 138 cases of drug-induced liver injury].
Lai RT; Wang H; Gui HL; Ye MZ; Dai WJ; Xiang XG; Zhao GD; Wang WJ; Xie Q
Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):185-9. PubMed ID: 22475136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
